Cytokinetics, Incorporated (CYTK): Price and Financial Metrics
GET POWR RATINGS... FREE!
CYTK POWR Grades
- CYTK scores best on the Quality dimension, with a Quality rank ahead of 53.56% of US stocks.
- The strongest trend for CYTK is in Growth, which has been heading down over the past 177 days.
- CYTK ranks lowest in Growth; there it ranks in the 5th percentile.
CYTK Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for CYTK is -0.88 -- better than only 5.27% of US stocks.
- With a price/sales ratio of 33.56, CYTOKINETICS INC has a higher such ratio than 95.54% of stocks in our set.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 35.83 for CYTOKINETICS INC; that's greater than it is for 99.03% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to CYTOKINETICS INC are MRNS, APLS, SAGE, FBIO, and PXLW.
- Visit CYTK's SEC page to see the company's official filings. To visit the company's web site, go to www.cytokinetics.com.
CYTK Valuation Summary
- In comparison to the median Healthcare stock, CYTK's EV/EBIT ratio is 257.58% lower, now standing at -10.4.
- CYTK's EV/EBIT ratio has moved up 3.2 over the prior 230 months.
Below are key valuation metrics over time for CYTK.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| CYTK | 2023-03-24 | 33.6 | -29.4 | -8.2 | -10.4 |
| CYTK | 2023-03-23 | 33.8 | -29.7 | -8.2 | -10.5 |
| CYTK | 2023-03-22 | 34.6 | -30.3 | -8.4 | -10.7 |
| CYTK | 2023-03-21 | 36.4 | -31.9 | -8.9 | -11.2 |
| CYTK | 2023-03-20 | 35.4 | -31.0 | -8.6 | -10.9 |
| CYTK | 2023-03-17 | 35.5 | -31.2 | -8.6 | -10.9 |
CYTK Growth Metrics
- The 3 year cash and equivalents growth rate now stands at 192.88%.
- Its 4 year net cashflow from operations growth rate is now at -380.62%.
- Its 3 year net cashflow from operations growth rate is now at -42.21%.
The table below shows CYTK's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 148.231 | -246.063 | -282.145 |
| 2022-06-30 | 151.153 | -200.793 | -215.921 |
| 2022-03-31 | 65.028 | -139.814 | -257.655 |
| 2021-12-31 | 70.428 | -142.522 | -215.314 |
| 2021-09-30 | 21.55 | -45.635 | -228.674 |
| 2021-06-30 | 57.801 | 7.502 | -155.763 |
CYTK's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- CYTK has a Quality Grade of C, ranking ahead of 30.43% of graded US stocks.
- CYTK's asset turnover comes in at 0.108 -- ranking 258th of 682 Pharmaceutical Products stocks.
- VRTX, INBP, and MBIO are the stocks whose asset turnover ratios are most correlated with CYTK.
The table below shows CYTK's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.108 | 1 | -0.236 |
| 2021-03-31 | 0.129 | 1 | -0.244 |
| 2020-12-31 | 0.149 | 1 | -0.286 |
| 2020-09-30 | 0.173 | 1 | -0.292 |
| 2020-06-30 | 0.077 | 1 | -0.445 |
| 2020-03-31 | 0.095 | 1 | -0.461 |
CYTK Price Target
For more insight on analysts targets of CYTK, see our CYTK price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $44.80 | Average Broker Recommendation | 1.5 (Moderate Buy) |
CYTK Stock Price Chart Interactive Chart >
CYTK Price/Volume Stats
| Current price | $34.98 | 52-week high | $55.80 |
| Prev. close | $34.53 | 52-week low | $32.96 |
| Day low | $33.98 | Volume | 803,723 |
| Day high | $35.60 | Avg. volume | 968,297 |
| 50-day MA | $40.79 | Dividend yield | N/A |
| 200-day MA | $44.08 | Market Cap | 3.33B |
Cytokinetics, Incorporated (CYTK) Company Bio
Cytokinetics, Incorporated, a clinical stage biopharmaceutical company, focuses on the discovery and development of novel small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. The company was founded in 1997 and is based in South San Francisco, California.
Latest CYTK News From Around the Web
Below are the latest news stories about CYTOKINETICS INC that investors may wish to consider to help them evaluate CYTK as an investment opportunity.
Cytokinetics Releases Inaugural Corporate Responsibility ReportReport Highlights Company Commitment to Patient Centricity, Sustainability, Ethics, Diversity, Equity and InclusionSOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the release of its inaugural Corporate Responsibility Report, outlining the Company's commitment to social and environmental responsibility, ethics and governance and patient and community engagement. “At Cytokinetics, being a responsible corporate citizen is a n |
Cytokinetics to Participate in Upcoming Investor ConferencesSOUTH SAN FRANCISCO, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor conferences: Oppenheimer 33rd Annual Healthcare Conference: Robert I. Blum, President and Chief Executive Officer, will present virtually on Monday, March 13, 2023 at 10:00 AM Eastern Time.Barclays Global Healthcare Conference: Robert I. Blum, President and Chief Executive Officer, will participate in a Fi |
Cytokinetics Posts Aficamten Data In Patients With Thickened Heart MuscleCytokinetics Incorporated (NASDAQ: CYTK) presented results from Cohort 4 of REDWOOD-HCM Phase 2 trial of aficamten in patients with non-obstructive hypertrophic cardiomyopathy (nHCM). At ten weeks, patients in Cohort 4 experienced significant improvements in NT-proBNP, with an average decrease of 66%. High-sensitivity troponin I level also improved significantly proportional to baseline at each study visit. Related: FDA Rejects Cytokinetics' Heart Failure Treatment Candidate. An improvement of ≥ |
Cytokinetics Presents Positive Results From Cohort 4 of REDWOOD-HCM and Long-Term Results From FOREST-HCM at the American College of Cardiology 72nd Annual Scientific SessionTreatment with Aficamten Resulted in Significant Improvements in Heart Failure Symptoms and Cardiac Biomarkers in Patients with Non-Obstructive HCM, Supporting Advancement to Phase 3 Additional Results from FOREST-HCM Demonstrate Long-Term Treatment with Aficamten for 48 Weeks is Well-Tolerated and Associated with Sustained Treatment Effect Company to Host Investor Event and Conference Call on March 6, 2023 at 8:30 AM Eastern Time SOUTH SAN FRANCISCO, Calif., March 04, 2023 (GLOBE NEWSWIRE) -- C |
Industry Analysts Just Upgraded Their Cytokinetics, Incorporated (NASDAQ:CYTK) Revenue Forecasts By 15%Shareholders in Cytokinetics, Incorporated ( NASDAQ:CYTK ) may be thrilled to learn that the analysts have just... |
CYTK Price Returns
| 1-mo | -18.29% |
| 3-mo | -23.29% |
| 6-mo | -28.51% |
| 1-year | -4.84% |
| 3-year | 197.70% |
| 5-year | 385.83% |
| YTD | -23.66% |
| 2022 | 0.53% |
| 2021 | 119.35% |
| 2020 | 95.85% |
| 2019 | 67.88% |
| 2018 | -22.45% |
Continue Researching CYTK
Want to see what other sources are saying about Cytokinetics Inc's financials and stock price? Try the links below:Cytokinetics Inc (CYTK) Stock Price | Nasdaq
Cytokinetics Inc (CYTK) Stock Quote, History and News - Yahoo Finance
Cytokinetics Inc (CYTK) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...